The difference in the tumor behavior is reflected in the latest WHO classification of head and neck tumors, in which HPV-positive and HPV-negative OPSCCs are classified as distinct clinical entities, using the overexpression of p16INK4a as a surrogate immunohistochemical marker for HPV status [13, 14]. This evidence concerns the gene CDKN2A and neoplasm.